Table 2 Demographic and clinical characteristics of patients in the anti-TNF and stem cell groups
Anti-TNF (n=39) | Stem cell (n=30) | p-value | |
|---|---|---|---|
Age, median (IQR) | 31.0 (25-34) | 26.0 (20-30.25) | 0.028 |
Sex | |||
Male | 29 (74.4%) | 14 (46.7%) | 0.019 |
Female | 10 (25.6%) | 16 (53.3%) | |
Montreal classification | |||
Age at onset | |||
A1 (≤16yr) | 15 (38.5%) | 6 (20.0%) | 0.098 |
A2 (17-40yr) | 24 (61.5%) | 24 (80.0%) | |
A3 (≥41yr) | 0 (0.0%) | 0 (0.0%) | |
Location | |||
L1 (Ileum) | 4 (10.3%) | 8 (26.7%) | 0.171 |
L2 (Colon) | 3 (7.7%) | 3 (10.0%) | |
L3 (Ileocolon) | 32 (82.1%) | 19 (63.3%) | |
Behavior | |||
B1 (Non-stricturing, non-penetrating) | 12 (30.8%) | 20 (66.7%) | 0.002 |
B2 (Stricturing) | 6 (15.4%) | 6 (20.0%) | |
B3 (Penetrating) | 21 (53.8%) | 4 (13.3%) | |
Albumin, mean±SD (g/dL) | 3.36±0.48 | 4.05±0.42 | <0.001 |
CRP, mean±SD (mg/dL) | 3.03±3.04 | 0.56±0.74 | <0.001 |
Fistula type | |||
Simple | 13 (33.3%) | 6 (20.0%) | 0.219 |
Complex | 26 (66.7%) | 24 (80.0%) | |
Multiple fistula | 15 (38.5%) | 13 (43.3%) | 0.683 |
Proctitis | 19 (48.7%) | 10 (33.3%) | 0.199 |
Stricture | 1 (2.6%) | 2 (6.7%) | 0.407 |
Abscess | 18 (46.2%) | 17 (56.7%) | 0.387 |
Medical treatment | |||
Immunomodulators | 16 (41.0%) | 15 (50.0%) | 0.458 |
Steroids | 2 (5.2%) | 0 (0.0%) | 0.208 |
Smoking | |||
Current smoker | 4 (10.3%) | 1 (3.3%) | 0.355 |
Ex-smoker | 8 (20.5%) | 4 (13.3%) | |
Previous fistula OP | 37 (94.9%) | 30 (100%) | 0.208 |
No. previous fistula OP, mean±SD (times) | 3.24±1.89 | 2.17±1.29 | 0.010 |
Interval from seton treatment to anti-TNF or stem cell therapy, mean±SD (months) | 1.03±0.93 | 16.13±16.01 | <0.001 |
Disease duration, mean±SD (years) | 9.37±6.13 | 6.10±4.88 | 0.018 |